Resources

In part 6, the conclusion of this Exclusive Interview, Todd Hobbs talks with Diabetes in Control Publisher Steve Freed about the upcoming focus on treating obesity as well as an oral form of semaglutide.

High cost associated with underuse in certain patient populations, particularly those with lower incomes.

How does the newest insulin delivery method compare to an established system?

Study targets breakfast habits of parents and its effects on their children.

Trial assesses if link exists between severe hypoglycemia and adverse cardiovascular outcomes in veterans.

Low levels thought to contribute to pathogenesis of painful diabetic peripheral neuropathy due to action on dorsal root ganglia.

Personalized messages based on motivational interviewing principles compared to usual care to determine if any significant difference in self-management of type 2 diabetes.

When is the HbA1c not reliable?

A. Recent blood transfusion
B. Renal failure
C. Medication use (e.g. aspirin)
D. G6PD deficiency
E. All of the above

Follow the link for the answer.

How do you choose the best, affordable treatment for each patient from 6 Million possible combinations for your patients with type 2?

Diabetes in Control is working with an endocrinologist and computer specialist who have developed a program to help you in deciding the best treatment option to manage blood glucose that the patient can afford using their insurance. They are looking for medical professionals to use it and provide feedback.

Would you be interested in learning about a free software that can go through 6 million possible drug combinations for patients with type 2, providing the best options for treatment using the patient’s medical information and insurance? It will rate each combination as to how much it could lower A1c, and provide the cost for each treatment, plus any side effects and even coupons, if available, for the patient to use. This program has already been used for hundreds of patients. See the software in action in a 9 minute video.

If you're interested in trying the software, email me at publisher@diabetesincontrol.com.

Follow the link to share your opinion or request more info.

I have a patient who has type 2 diabetes. He was started on long-acting insulin 8 months ago. Before adding the insulin, he was taking a daily GLP-1. He had experienced diabetic ketoacidosis (DKA) while on a SGLT-2, and did not tolerate metformin due to GI side effects. Therefore, these …